Product Information
ROPINIROLE HCL 3 MG TABLET is a generic product labeled by Bionpharma Inc., priced at $0.0768 per EA under NDC 69452036020. Its NADAC has been published 178 times since May 10, 2023.
FDA first approved this application on Nov 28, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3 mg/1
Manufacturer
Bionpharma Inc.NDC
69452036020
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ROPINIROLE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA079229FDA Approved
11/28/2012
TE Code
AB
On Market Since
9/15/2022
Pharmacological Classes
Price Statistics
The NADAC for ROPINIROLE HCL 3 MG TABLET has been published 178 times since May 10, 2023, and over the history we have for it it has declined 21.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0768 per EA |
|---|---|
| All-time high | $0.0977 (May 10, 2023) |
| All-time low | $0.0575 (Nov 20, 2024) |
| 52-week high | $0.0848 |
| 52-week low | $0.0768 |
| Median price | $0.0803 |
| Average price | $0.0797 |
| Largest weekly change | -28.2% (Nov 20, 2024) |
| Weeks tracked | 178 |
| Tracking since | May 10, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Ropinirole market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bionpharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ropinirole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonergot Dopamine Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROPINIROLE HCL 3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROPINIROLE HCL 3 MG TABLET, manufactured by Bionpharma Inc., is $0.0768 per EA (NDC 69452036020), effective Sep 30, 2026.
How has the price of ROPINIROLE HCL 3 MG TABLET changed over time?
Over the history we have for it, the NADAC for ROPINIROLE HCL 3 MG TABLET has declined 21.4%. It has been tracked across 178 weekly CMS publications since May 10, 2023.
What are the highest and lowest recorded NADAC prices for ROPINIROLE HCL 3 MG TABLET?
Since May 10, 2023, the NADAC for ROPINIROLE HCL 3 MG TABLET has ranged from a low of $0.0575 (Nov 20, 2024) to a high of $0.0977 (May 10, 2023), with a median of $0.0803 per EA.
Are there cheaper alternatives to ROPINIROLE HCL 3 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ROPINIROLE HCL 3 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ROPINIROLE HCL 3 MG TABLET?
ROPINIROLE HCL 3 MG TABLET (NDC 69452036020) is labeled by Bionpharma Inc., and CMS classifies it as a generic product.